Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 9;13(4):643.
doi: 10.3390/diagnostics13040643.

Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies

Ha Nui Kim  1 , Jung Yoon  1 , Woong Sik Jang  1 , Chae Seung Lim  1
Affiliations

Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies

Ha Nui Kim et al. Diagnostics (Basel). .

Abstract

The accurate detection of anti-neutralizing SARS-CoV-2 antibodies can aid in the understanding of the development of protective immunity against COVID-19. This study evaluated the diagnostic performance of the RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test. Using the 90% plaque reduction neutralization test (PRNT90) as a reference, 200 serum samples collected from 78 COVID-19-positive and 122 COVID-19-negative patients were divided into 76 PRNT90-positive and 124 PRNT90-negative groups. The ability of the RapiSure test to detect antibodies was compared to that of the STANDARD Q COVID-19 IgM/IgG Plus test and that of PRNT90. The positive, negative, and overall percent agreement between the RapiSure and STANDARD Q test was 95.7%, 89.3%, and 91.5%, respectively, with a Cohen's kappa of 0.82. The RapiSure neutralizing antibody test results revealed a sensitivity of 93.4% and a specificity of 100% compared to the PRNT results, with an overall percent agreement of 97.5% and Cohen's kappa of 0.95. The diagnostic performance of the RapiSure test was in good agreement with the STANDARD Q COVID-19 IgM/IgG Plus test and comparable to that of the PRNT. The RapiSure S1 RBD IgG/Neutralizing Ab Test was found to be convenient and reliable and, thus, can provide valuable information for rapid clinical decisions during the COVID-19 pandemic.

Keywords: COVID-19 antibodies; SARS-CoV-2; neutralizing antibodies; rapid chromatographic immunoassay.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram and images of the RapiSure COVID-19 S1 RBD IgG/Neutralizing Ab Test. (a) S1 RBD IgG; (b) neutralizing antibody; and (c) images of the RapiSure COVID-19 S1 RBD IgG/Neutralizing Ab Test using representative serum samples with positive, weakly positive, and negative results from left to right.
Figure 1
Figure 1
Schematic diagram and images of the RapiSure COVID-19 S1 RBD IgG/Neutralizing Ab Test. (a) S1 RBD IgG; (b) neutralizing antibody; and (c) images of the RapiSure COVID-19 S1 RBD IgG/Neutralizing Ab Test using representative serum samples with positive, weakly positive, and negative results from left to right.
Figure 2
Figure 2
Sensitivity (%) of the RapiSure COVID-19 S1 RBD IgG/Neutralizing Ab Test in three groups: <7 days, 8–14 days, and >15 days after onset of illness. Blue bars represent the results for S1 RBD IgG; gray bars represent the results for nAbs, of which each upper light-colored bar represents a false negative result.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. WHO Statement on the Twelfth Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Coronavirus Disease (COVID-19) Pandemic. [(accessed on 29 September 2022)]; Available online: https://www.who.int/news/item/12-07-2022-statement-on-the-twelfth-meetin....
    1. Kraay A.N., Nelson K.N., Zhao C.Y., Demory D., Weitz J.S., Lopman B.A. Modeling serological testing to inform relaxation of social distancing for COVID-19 control. Nat. Commun. 2021;12:7063. doi: 10.1038/s41467-021-26774-y. - DOI - PMC - PubMed
    1. dos Santos Ferreira C.E., Gómez-Dantés H., Junqueira Bellei N.C., López E., Nogales Crespo K.A., O’Ryan M., Villegas J. The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. Viruses. 2021;13:2391. doi: 10.3390/v13122391. - DOI - PMC - PubMed
    1. Valkenburg S.A., Leung N.H., Bull M.B., Yan L.-m., Li A.P., Poon L.L., Cowling B.J. The hurdles from bench to bedside in the realization and implementation of a universal influenza vaccine. Front. Immunol. 2018;9:1479. doi: 10.3389/fimmu.2018.01479. - DOI - PMC - PubMed
    1. Addetia A., Crawford K.H., Dingens A., Zhu H., Roychoudhury P., Huang M.-L., Jerome K.R., Bloom J.D., Greninger A.L. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 2020;58:e02107–e02120. doi: 10.1128/JCM.02107-20. - DOI - PMC - PubMed

LinkOut - more resources